Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Change in Acquisitions & Divestments (2020 - 2025)

Arcutis Biotherapeutics has reported Change in Acquisitions & Divestments over the past 6 years, most recently at $55.0 million for Q4 2025.

  • Quarterly results put Change in Acquisitions & Divestments at $55.0 million for Q4 2025, down 3.97% from a year ago — trailing twelve months through Dec 2025 was $227.4 million (down 21.25% YoY), and the annual figure for FY2025 was $227.4 million, down 21.25%.
  • Change in Acquisitions & Divestments for Q4 2025 was $55.0 million at Arcutis Biotherapeutics, up from $43.3 million in the prior quarter.
  • Over the last five years, Change in Acquisitions & Divestments for ARQT hit a ceiling of $147.5 million in Q1 2023 and a floor of $36.0 million in Q3 2021.
  • Median Change in Acquisitions & Divestments over the past 5 years was $67.6 million (2022), compared with a mean of $74.6 million.
  • Biggest five-year swings in Change in Acquisitions & Divestments: skyrocketed 317.0% in 2021 and later tumbled 52.86% in 2024.
  • Arcutis Biotherapeutics' Change in Acquisitions & Divestments stood at $72.0 million in 2021, then increased by 11.68% to $80.4 million in 2022, then tumbled by 30.36% to $56.0 million in 2023, then grew by 2.28% to $57.3 million in 2024, then decreased by 3.97% to $55.0 million in 2025.
  • The last three reported values for Change in Acquisitions & Divestments were $55.0 million (Q4 2025), $43.3 million (Q3 2025), and $60.7 million (Q2 2025) per Business Quant data.